S
Steve Lefever
Researcher at Ghent University
Publications - 47
Citations - 2560
Steve Lefever is an academic researcher from Ghent University. The author has contributed to research in topics: RNA & Gene. The author has an hindex of 20, co-authored 43 publications receiving 1950 citations. Previous affiliations of Steve Lefever include Ghent University Hospital.
Papers
More filters
Journal ArticleDOI
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Ashton C. Berger,Anil Korkut,Rupa S. Kanchi,Apurva M. Hegde,Walter F. Lenoir,Wenbin Liu,Yuexin Liu,Huihui Fan,Hui Shen,Visweswaran Ravikumar,Arvind Rao,Andre Schultz,Xubin Li,Pavel Sumazin,Cecilia Williams,Pieter Mestdagh,Preethi H. Gunaratne,Christina Yau,Reanne Bowlby,A. Gordon Robertson,Daniel Guimarães Tiezzi,Chen Wang,Andrew D. Cherniack,Andrew K. Godwin,Nicole M. Kuderer,Janet S. Rader,Rosemary E. Zuna,Anil K. Sood,Alexander J. Lazar,Akinyemi I. Ojesina,Clement Adebamowo,Sally N. Adebamowo,Keith A. Baggerly,Ting-Wen Chen,Hua-Sheng Chiu,Steve Lefever,Liang Liu,Karen L. MacKenzie,Sandra Orsulic,Jason Roszik,Carl Simon Shelley,Qianqian Song,Christopher P. Vellano,Nicolas Wentzensen,John N. Weinstein,Gordon B. Mills,Douglas A. Levine,Rehan Akbani +47 more
TL;DR: Using 16 key molecular features, five prognostic subtypes were identified and a decision tree that classified patients into the subtypes based on just six features that are assessable in clinical laboratories was developed, raising potential implications for immunotherapy.
Journal ArticleDOI
CEP290, a gene with many faces: mutation overview and presentation of CEP290base.
TL;DR: CEP290base is developed, a locus‐specific mutation database that links mutations with patients and their phenotypes, and provides an overview of all CEP290 mutations identified so far, with their associated phenotypes.
Journal ArticleDOI
A mechanistic classification of clinical phenotypes in neuroblastoma
Sandra Ackermann,Sandra Ackermann,Maria Cartolano,Barbara Hero,Anne Welte,Anne Welte,Yvonne Kahlert,Yvonne Kahlert,Andrea Roderwieser,Andrea Roderwieser,Christoph Bartenhagen,Christoph Bartenhagen,Esther Walter,Esther Walter,Judith Gecht,Laura Kerschke,Ruth Volland,Roopika Menon,Johannes M. Heuckmann,Moritz Gartlgruber,Sabine Hartlieb,Kai-Oliver Henrich,Konstantin Okonechnikov,Janine Altmüller,Peter Nürnberg,Steve Lefever,Bram De Wilde,Frederik Sand,Frederik Sand,Fakhera Ikram,Fakhera Ikram,Fakhera Ikram,Carolina Rosswog,Carolina Rosswog,Janina Fischer,Janina Fischer,Jessica Theissen,Falk Hertwig,Aatur D. Singhi,Thorsten Simon,Wenzel Vogel,Sven Perner,Barbara Krug,Matthias Schmidt,Sven Rahmann,Sven Rahmann,Viktor Achter,Ulrich Lang,Christian Vokuhl,Monika Ortmann,Reinhard Büttner,Angelika Eggert,Franki Speleman,Roderick J. O’Sullivan,Roman K. Thomas,Frank Berthold,Jo Vandesompele,Alexander Schramm,Frank Westermann,Johannes H. Schulte,Martin Peifer,Matthias Fischer,Matthias Fischer +62 more
TL;DR: This work sequenced more than 400 pretreatment neuroblastomas and identified molecular features that characterize the three distinct clinical outcomes, and proposed a mechanistic classification of neuroblastoma that may benefit the clinical management of patients.
Journal ArticleDOI
Correction: Corrigendum: Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay
Wim Trypsteen,Pejman Mohammadi,Clarissa Van Hecke,Pieter Mestdagh,Steve Lefever,Yvan Saeys,Pieter De Bleser,Jo Vandesompele,Angela Ciuffi,Linos Vandekerckhove,Ward De Spiegelaere +10 more
TL;DR: In this Article, Yvan Saeys is incorrectly listed as being affiliated with ‘Department of Biomedical Molecular Biology Ghent University, Ghent, Belgium’.
Journal ArticleDOI
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Iuliia Efimova,Elena Catanzaro,Louis Van der Meeren,Victoria D. Turubanova,Hamida Hammad,Tatiana A. Mishchenko,Maria Vedunova,Carmela Fimognari,Claus Bachert,Frauke Coppieters,Steve Lefever,Andre G. Skirtach,Olga Krysko,Dmitri V. Krysko +13 more
TL;DR: It is demonstrated for the first time that ferroptosis is immunogenic in vitro and in vivo, and thus broadens the current concept of immunogenic cell death and opens the door for the development of new strategies in cancer immunotherapy.